Silver Book Fact

TAVR v. SAVR in Intermediate-Risk SAS Patients

At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical aortic valve replacement (SAVR)), disabling stroke rates of 2.3% (compared to 5.9% for SAVR), and rehospitalization rates of 11.4% (compared to 15.1% for SAVR).

Thourani V, Kodali S, Makkar R, et al. Transcatheter Aortic Valve Replacement Versus Surgical Valve Replacement in Intermediate-Risk Patients: A propensity score analysis. Lancet. 2016; 387(10034): 2218-25. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30073-3/references

Reference

Title
Transcatheter Aortic Valve Replacement Versus Surgical Valve Replacement in Intermediate-Risk Patients: A propensity score analysis
Publication
Lancet
Publication Date
2016
Authors
Thourani V, Kodali S, Makkar R, et al
Volume & Issue
Volume 387, Issue 10034
Pages
2218-25
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Undertreatment of patients with sSAS
    AS is often undertreated — one study found that 56% of severe symptomatic aortic stenosis (sSAS) patients referred to a cardiothoracic surgeon were not operated on.  
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • Survival Rates of SAS Patients with and without SAVR
    Patients with severe aortic stenosis (SAS) ages 80+ who underwent surgical aortic valve replacement (SAVR) have 1-year, 2-year, and 5-year survival rates of 87%, 78%, and 68% respectively — compared with…  
  • Life expectancy and quality of life gains from AVR
    A study of 4,617 patients who underwent aortic valve replacement (AVR) over a period of 20 years found significant gains in life expectancy and quality of life — 43,166 net life-years…  
  • Satisfaction with HVD Treatment
    Among treated heart valve disease (HVD), 96% express “full satisfaction” and 78% are “very satisfied” with their treatment.